Basi molecolari e applicazioni cliniche della determinazione dell'antigene 3 del carcinoma prostatico (PCA3)

Translated title of the contribution: Molecular bases and clinical applications of prostate cancer antigen 3 (PCA3) determination

Maurizio Ferrari, Ivana Spiga

Research output: Contribution to journalArticle

Abstract

Prostate cancer is one of the leading causes of death in men. Although the prostate-specific antigen (PSA) test has significantly improved the detection of prostate cancer, its low specificity results in a high number of false positive and subsequently in unnecessary prostate biopsies. The PCA3, discovered in 1999, is a non-coding RNA that is overexpressed in prostate cancer. Quantitative analysis of PCA3 mRNA in urine was found to be a good predictor of the outcome of prostate biopsies. The test, based on transcription-mediated amplification (TMA) on urine collected after a digital rectal examination, has high specificity and is particularly useful in patients with a previous negative biopsy. Recently, some studies have suggested that PCA3 may also have a prognostic value and could be utilized in the initial decision for biopsy.

Translated title of the contributionMolecular bases and clinical applications of prostate cancer antigen 3 (PCA3) determination
Original languageItalian
Pages (from-to)356-362
Number of pages7
JournalBiochimica Clinica
Volume35
Issue number5
Publication statusPublished - Oct 2011

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Molecular bases and clinical applications of prostate cancer antigen 3 (PCA3) determination'. Together they form a unique fingerprint.

  • Cite this